H emoptysis is defined as the expectoration of blood and is classified into mild, moderate, and severe based on the amount and rate of blood loss. Clinical parameters, such as need for blood product transfusion, and hemodynamic or respiratory compromise, should also be included in the overall assessment of severity, particularly since no consensus regarding cutoff values are available. 1 Severe bleeding occurs in 5% to 15% of all cases and constitutes a medical emergency as even small volumes of blood inside the airways can lead to rapid asphyxiation. Bleeding can be idiopathic, drug-induced, related to trauma, coagulopathy and primary, or secondary lung diseases; it may also present as a complication of diagnostic and interventional bronchoscopy. 2 If severe hemoptysis is present, the goal should be to maintain adequate oxygenation and ventilation while attempts are made to control the bleeding. The first step is to secure the airway; this is accomplished by using the largest possible diameter endotracheal tube available or a rigid bronchoscope. Larger diameter endotracheal tubes are preferred over double lumen tubes as they provide superior access for diagnostic and therapeutic interventions. 3 If the site of bleeding is known, the bed should be tilted with the site of bleeding down (closer to the floor) to prevent spillage of blood into the nonbleeding lung.
Bronchoscopy remains a cornerstone in the management of airway bleeding, it provides diagnostic information, allows for minimally invasive treatments to occur and guides interventional radiologists and thoracic surgeons when planning for urgent and emergent procedures if these are indicated. Mild and moderate cases of hemoptysis may be managed with flexible bronchoscopy; rigid bronchoscopy is the preferred modality in severe cases. The latter should be performed by a skilled physician and only after careful evaluation of individual cases, particularly in the setting of hemodynamic or respiratory compromise. Rigid bronchoscopy has the advantage of securing the airway and providing an access for ventilation while simultaneously allowing the use of large suction catheters and therapeutic tools. Flexible and rigid bronchoscopes are often used in combination. 1, 4 In certain cases the severity of bleeding may preclude the use of bronchoscopy completely; immediate consideration for angioembolization and surgical consultation is indicated in such circumstances.
Bleeding as a complication of flexible bronchoscopy is uncommon, minor, and severe bleeding occur in 0.19% and 0.26% of bronchoscopies respectively. 5 The risk however, increases significantly when performing endobronchial and transbronchial lung biopsies and depending on the baseline characteristics of the patient, bleeding may be seen in 1.9% to 9% of cases. 6, 7 With the growth of the field of interventional pulmonology, procedure-related bleeding is a complication that the advanced bronchoscopist should be ready to address. 5 Bleeding encountered during therapeutic bronchoscopy for malignant airway obstruction which requires interventions is uncommon, presenting in only 0.5% of cases. 8 Procedure-related bleeding can be classified as mild, moderate, or severe based on the interventions required to control it. This approach may be more suitable than the traditional quantification of bleeding as aspiration of saline solution, epinephrine and secretions makes volume assessment inaccurate, and in the case of severe or rapid bleeding, volume assessment is trumped by the bronchoscopist's assessment of the bleeding.
DESIGN Objective
To report the feasibility of endobronchial instillation of an absorbable gelatin and thrombin slurry (GTS) in cases of spontaneous hemoptysis and procedure-related bleeding.
Methods
After obtaining Institutional Review Board/ Privacy Board (IRB/PB) approval (approval number WA0109-15), we screened the institutional operating and endoscopy room database at Memorial Sloan Kettering Cancer Center from January 2010 to April 2017 for bronchoscopic procedures performed by the Pulmonary or Thoracic Surgery services and using the keyword "Gelfoam plus." Patient consent was waived by our internal IRB based on the retrospective nature of the study.
Bronchoscopy reports, operating room (OR) and anesthesia records, and progress notes were reviewed for pertinent information. We classified airway bleeding as mild (< 20 mL/24 h), moderate (20 to 100 mL/24 h) and severe ( > 100 mL/ 24 h; bleeding associated with hemodynamic compromise or respiratory failure; bleeding identified during bronchoscopy which persists despite standard bronchoscopic measures (SBM) including bronchoscopic tamponade, instillation of epinephrine and cold saline and/or requires placement of balloon-occlusion devices; and at the discretion of the bronchoscopist based on the rate of bleeding and assessment of individual cases). We collected hemostasis rates. Failure to achieve hemostasis was determined when persistent bleeding was identified bronchoscopically despite all measures; postbronchoscopic balloon occlusion with an inflated balloon was required; or when immediate angioembolization or surgery was required. We followed patients for up to 30 days for adverse events attributed to GTS instillation, recurrence of bleeding (defined as spontaneous hemoptysis or fresh blood visible in the endotracheal tube) and cause of death.
Technique Description
We consider using GTS in cases of spontaneous hemoptysis or procedure-related bleeding which do not subside after SBM. We also consider it in cases in which the bleeding is severe enough that SBM may not be feasible or effective due to profuse bleeding. GTS may be used concomitantly with balloon occlusion based on the severity or persistence of the bleeding at the discretion of the bronchoscopist We prepare the slurry using the components available in the GELFOAM PLUS kit (Baxter Healthcare Corporation product 1501341, listing price for 1 kit $189.00). This includes absorbable gelatin, lyophilized thrombin powder, 2 prefilled 10 mL saline solution syringes, and a vial access device (Fig. 1A) . Package is stored in the OR supply area and in the bronchoscopy suite under manufacturer recommendations (temperature 15 to 25°C, 59 to 77°F); no refrigeration is required. Slurry is formed during bronchoscopy immediately before its administration. Time needed to reconstitute components is ∼1 to 2 minutes. No particular difficulties are encountered during process and authors believe that proficiency can be attained after 2 to 3 procedures.
We first cut absorbable gelatin into small pieces (5×5 mm) and place them in a specimen cup. We then reconstitute thrombin powder using one of the prefilled 10 mL saline solution syringes and combine it with the gelatin in the specimen cup. Mixture is stirred until gelatin in soaked with thrombin and is then transferred into a 10-mL syringe. Finally, we connect this syringe to an empty 10-mL syringe via a 3-way stopcock. The mixture is then agitated repeatedly between syringes until a slurry is formed (Figs. 1B, C) .
GT is instilled through the working channel of the bronchoscope (Fig. 1D ), either directly onto the bleeding surface or into the distal airways, and followed by epinephrine (1:10,000 to 1:50,000) solution to assure complete delivery of the mixture. Saline can also be used for this however, we advocate using epinephrine due to the potential additional hemostatic effect. Occlusion with a bronchial blocker is carried out simultaneously, if deemed necessary. If a bronchial blocker with a distal port is placed, the slurry may also be instilled through this port in similar manner at the discretion of the bronchoscopist. We maintain regular cleaning and processing protocols for bronchoscopes after using GTS. No additional processing was implemented.
RESULTS
We identified 13 cases in which Gelfoam Plus kit was used from June 2010 to April 2017 for bronchoscopic hemostasis. One patient had GTS instillation on 2 separate occasions. The median age was 69 years (range, 52 to 79 y); 6 female and 7 male. Spontaneous bleeding was found in 8 cases. Of these, one was secondary to bleeding from a surgical stump; others were due to central or distal malignant airway disease. Procedure-related bleeding was encountered in 5 cases and was related to debulking of obstructing endobronchial tumor, transbronchial lung biopsy, or incidentally upon contact with an endobronchial mass. Bleeding was considered severe in 9 cases (70%), moderate in 2 cases (15%), and mild in 2 cases (15%) based on our predefined classification. No patient was receiving therapeutic anticoagulation at the time of bronchoscopy and no significant coagulopathy was recorded (Table 1) .
Three cases had GTS instillation through the distal port of a bronchial blocker. Remaining cases had instillation through the working channel of a flexible bronchoscope. Of these, 4 had concomitant Fogarty balloon occlusion. Hemostasis was achieved bronchoscopically in 10 cases (77%). A bronchial blocker was left in place preemptively in 2 of these cases but remained deflated. Most cases used additional SBM to achieve hemostasis. Epinephrine was used in 11 cases (84%) and tamponade with an embolectomy balloon (Fogarty Edwards Lifesciences, 8/14 French model number 62080814F) and/or a bronchial blocker (Arndt Endobronchial Blocker Cook Medical, 9 French model number A-AEBS-9.0-78-SPH-AS) was used in 9 cases (70%). Two cases also used endobronchial oxidized cellulose polymer (Surgicel Ethicon) placed bronchoscopically, and 2 cases used > 1 Gelfoam Plus kit. Recurrence of bleeding was seen in 50% of cases in which hemostasis was initially achieved, a procedure (therapeutic flexible bronchoscopy) was required in only one of these.
Failure to achieve hemostasis was encountered in 3 cases (23%), 1 with spontaneous hemoptysis and 2 with procedure-related bleeding. All of these cases required postbronchoscopy bronchial balloon occlusion. Two required referral to interventional radiology for embolization and 1 had spontaneous resolution without further interventions. No patients required surgery in our study ( Table 2) . Most cases presented abnormal findings on chest x-ray, such as parenchymal lesions, bleeding, atelectasis, and pleural effusions, before bronchoscopy and GTS instillation. No readily discernible changes were noted in the cases where comparative images were available. In the cases where no preceding abnormal radiographic findings were visible, it is difficult to ascertain if changes were due to GTS instillation with subsequent atelectasis, or to other factors such as bleeding or balloon occlusion. Three patients died within 30 days; 2 in the group that achieved hemostasis and 1 in the group which did not. Evident recurrent contributory bleeding at the time of death was seen in the latter case; all deaths were related to their underlying malignancy. No complications attributable to the use of GTS were identified; these included postobstructive pneumonia, respiratory failure attributed to airway obstruction, dislodgement of GTS clot, inability to remove clot if subsequent bronchoscopy was performed. Four cases had repeat bronchoscopy to ascertain hemostasis and/ or to deflate a bronchial blocker 24 to 48 hours after initial instillation. Three of these had visible clot which was removed successfully and without difficulty, one had no visible clot. No dislodgment into a different segment was appreciated in any case. Finally, no damage to bronchoscope equipment attributable to GTS instillation was encountered.
DISCUSSION
Multiple bronchoscopic techniques can be used to achieve permanent hemostasis or as temporary measures while more definitive treatments are pursued. Iced saline lavage with 500 to 1000 mL has been successfully used in cases of hemoptysis. 9 Small volumes of cold saline (10 to 15 mL) and/or topical epinephrine (1:10,000 to 1:50,000) are also recommended to achieve hemostasis in cases of mild to moderate bleeding complicating transbronchial lung biopsy. 7 Attention should be paid as hypertension and life-threatening arrhythmias can occur when using epinephrine bronchoscopically. 10 Antidiuretic hormone derivatives were evaluated as alternatives to epinephrine; terlipressin was related to insignificant changes in heart rate and blood pressure, whereas ornipressin was not related to hemodynamic changes. 11 In cases of severe bleeding however, topical epinephrine and cold saline are washed off due to profuse bleeding and thus their vasoconstrictive effect is diminished by the inability to reach the intended target. In such instances, balloon-occlusion devices may prove life-saving. These are catheters with a distal inflatable balloon which is selectively placed in the intended airway. The right or left mainstem bronchi and bronchus intermedius are preferred over distal airways due to ease of placement and lower risk of dislodgment. Once placed, they can isolate the bleeding segment, protect the nonbleeding lung, and allow further interventions to be planned, all while providing a tamponading effect. Different balloon-occlusion devices are available. An embolectomy balloon can be inserted through the working channel of a flexible bronchoscope (8 French catheter requires at least a 2.8 mm working channel) or alongside the endotracheal tube if intubation has been performed. This is a temporary measure only as the catheter is not anchored and may dislodge inadvertently. If prolonged occlusion is needed, a bronchial blocker can be placed through an endotracheal tube and secured to it via a special adapter. The balloon may also remain deflated to prevent mucosal necrosis, and be inflated if bleeding recurs. A distal port which is available in bronchial blockers can be used for aspiration and instillation of products. 1, 4, 12 Thermal therapies, such as argon plasma coagulation or lasers are valuable tools to control bleeding. However, their benefit is limited to cases in which the bleeding surface is identifiable and their energy can be focused. In cases of distal or profuse bleeding, their benefit is lessened.
Multiple newer techniques have been used to control bleeding bronchoscopically. These include instillation of tranexamic acid, local delivery of silicone spigots or oxidized regenerated cellulose mesh, and other biologically active agents. [13] [14] [15] [16] [17] In 1 study, the combination of thrombin and fibrinogen achieved immediate local control in all patients with severe spontaneous hemoptysis; longterm control was achieved in 70%. 18 Instillation of n-butyl cyanoacrylate to form a sealant glue led to local control in all patients presenting with massive hemoptysis. 19 None of the patients in these reports however, had bleeding related to therapeutic bronchoscopy and in only one of them the etiology of bleeding was bronchogenic carcinoma.
To our knowledge this is the first report of using GTS bronchoscopically to achieve hemostasis. The decision to proceed with instillation is based on the individual case, clinical judgement, and experience of the bronchoscopist, rather than predefined limits of blood loss volume. We consider using it in cases of hemoptysis or procedurerelated bleeding which do not subside after SBM; it may be used alone and concomitantly with balloon occlusion. Two cases did not receive epinephrine before GTS. One case was due to severe bleeding due to a pulmonary artery pseudoaneurysm, in this case bleeding was profuse and immediate balloon occlusion was required. Attempting to control such profuse bleeding with standard measures would not have been clinically indicated. The second case corresponded to bleeding originating from a surgical stump with possible fistulization. Thoracic surgeon considered that a more permanent approach was required and therefore GTS was used instead of epinephrine.
Absorbable gelatin is a dried hydrocolloid made from porcine-derived collagen and presented in powder or sponge forms. It can absorb 40 times its weight and expands to 200% its initial dimensions. It becomes liquefied within a week and is completely absorbed in 4 to 6 weeks. It is applied alone or in combination with thrombin directly onto the bleeding surfaces to achieve hemostasis. Its use is extensively reported in surgical literature. 20, 21 Thrombin was approved for topical use in surgery by the US Food and Drug Administration (FDA) in the 1970s. It was initially generated from bovine source however, due to higher risk of antibody formation it is now pooled from human plasma. Risk of viral infection transmission is still present, although very low. Thrombin is presented as a lyophilized sterile, nonpyrogenic powder which is reconstituted with saline solution.
GTS can be instilled via the working channel of the bronchoscope and directed to the source of bleeding (ie, segmental bronchus when performing transbronchial biopsy or central airway target for malignant airway obstruction); this can be followed by balloon occlusion if deemed necessary by the bronchoscopist. It can also be delivered via the distal port of a bronchial blocker when one is in place.
We believe the ease of delivery, expansibility and clot formation properties of GTS to be some of the reasons it can help achieve hemostasis. It can be particularly useful in addition to SBM in cases of distal, unidentifiable bleeding originating from subsegmental airways (ie, spontaneous bleeding from distal malignant airway disease, bronchiectasis, and posttransbronchial biopsy) as the delivery can be directed to the culprit area. It may also be beneficial in cases of sudden bleeding due to procedures, particularly in conjunction with balloon occlusion when rapid measures are required. Solution can be prepared while balloon occlusion in underway.
Hemostasis was achieved in 10 (77%) of our cases. SBM were used in most cases, in 2 cases Surgicel was also used bronchoscopically. Hemostasis rates could therefore be related to any specific strategy or to the combination. Further studies comparing SBM and the combination with GTS would be valuable. Despite a high recurrence rate, only 1 case required further interventions. Overall, hemoptysis due to malignancy is likely to recur and therefore recurrence may not be an adequate outcome to investigate. Need for angioembolization or surgery and death from asphyxiation may be more adequate parameters to measure in comparative studies.
In 3 of 4 cases where bronchoscopy was performed to verify hemostasis and/or deflate a bronchial blocker we identified GTS clot formation in the intended area, this was successfully and easily removed. Whether dislodgment occurred in any of the cases in which a repeat bronchoscopy was not performed remains unknown. We cannot confirm complete dissolution of the mixture in 4 to 6 weeks as a repeat bronchoscopy was not routinely performed at this interval. Further studies investigating how rapidly GTS is absorbed in the tracheobronchial tree are needed. No immediate or remote complications attributable to this technique were identified.
The main limitations of our study include its retrospective, noncontrolled design, and small sample size. SBM were used in the majority of our patients and therefore the hemostasis rate seen in our cases could be attributed to their respective effects and not due to GTS alone. Procedures were performed at a referral cancer center by fellowship-trained interventional pulmonologists or thoracic surgeons, all with extensive experience in performing flexible and rigid bronchoscopy and in managing patients with large-volume hemoptysis. Finally, general anesthesia was used in all cases and most were performed in an OR.
During our study, we found that instillation of GTS through the working channel of the bronchoscope or distal port of a bronchial blocker is feasible. Preparation of the slurry is simple and can be performed by an assistant in the bronchoscopy suite or OR. It can be used in cases of spontaneous hemoptysis and procedure-related bleeding. Larger studies are required before general recommendations can be made.
CONCLUSIONS
Endobronchial instillation of an absorbable GTS for the management of spontaneous hemoptysis and procedure-related bleeding is feasible. The slurry may be delivered through the working channel of the flexible bronchoscope or through the distal port on a bronchial blocker. Further studies are needed before routine use is recommended.
